Study: NCT04112589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 intravenous days 1 to 4 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 intravenous days 1 to 4 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 intravenous days 1 to 4 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 intravenous days 1 to 4 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/ 2 intravenous days 1 to 3 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/ 2 intravenous days 1 to 3 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/ 2 intravenous days 1 to 3 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/ 2 intravenous days 1 to 3 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycosylated G-CSF
Description: daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycosylated G-CSF
Description: daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycosylated G-CSF
Description: daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycosylated G-CSF
Description: daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle